Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease

被引：115

作者：

Boyman, Onur ^{[1
]}

Surh, Charles D. ^{[1
]}

Sprent, Jonathan ^{[1
]}

机构：

[1] CHU Vaudois, Div Immunol & Allergy, CH-1011 Lausanne, Switzerland

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2006年 / 6卷 / 12期

关键词：

activation-induced cell death; autoimmune disease; autoimmunity; cancer; cytokine-binding protein(s); IL-2; immune complexes; immune modulation; memory T cell; T regulatory cell;

D O I：

10.1517/14712598.6.12.1323

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Initially discovered as a potent T cell proliferation factor, IL-2 was soon used for cancer immunotherapy, especially for metastatic melanoma and renal cell carcinoma; however, the severe side effects of IL-2 therapy, plus the negative role of IL-2 in maintaining of CD4(+) CD25(+) T regulatory cells (Tregs), has somewhat dampened enthusiasm for using IL-2 in immunotherapy. This opinion article discusses the possibility of combining IL-2 with certain anti-IL-2 antibodies for reducing the dose of IL-2 needed and preferentially stimulating effector T cells, but not Tregs, an approach that might provide an improved strategy for anticancer immunotherapy. Alternatively, complexes of IL-2 with other anti-IL-2 antibodies can selectively stimulate Tregs and could, therefore, be useful for treating autoimmune diseases.

引用

页码：1323 / 1331

页数：9

共 72 条

[1] Fusokine interleukin-2/interleukin-18, a novel potent innate and adaptive immune stimulator with decreased toxicity [J].

Acres, B ;

Gantzer, M ;

Remy, C ;

Futin, N ;

Accart, N ;

Chaloin, O ;

Hoebeke, J ;

Balloul, JM ;

Paul, S .

CANCER RESEARCH, 2005, 65 (20) :9536-9546

[2] IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients [J].

Ahmadzadeh, M ;

Rosenberg, ST .

BLOOD, 2006, 107 (06) :2409-2414

[3]

ANDERSON PM, 1992, J IMMUNOTHER, V12, P19

[4]

ANDERSON TD, 1988, LAB INVEST, V59, P598

[5] CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2 [J].

Antony, PA ;

Restifo, NP .

JOURNAL OF IMMUNOTHERAPY, 2005, 28 (02) :120-128

[6] CD8+T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells [J].

Antony, PA ;

Piccirillo, CA ;

Akpinarli, A ;

Finkelstein, SE ;

Speiss, PJ ;

Surman, DR ;

Palmer, DC ;

Chan, CC ;

Klebanoff, CA ;

Overwijk, WW ;

Rosenberg, SA ;

Restifo, NP .

JOURNAL OF IMMUNOLOGY, 2005, 174 (05) :2591-2601

[7] Interleukin 2-dependent mechanisms of tolerance and immunity in vivo [J].

Antony, Paul A. ;

Paulos, Chrystal M. ;

Ahmadzadeh, Mojgan ;

Akpinarli, Akgul ;

Palmer, Douglas C. ;

Sato, Noriko ;

Kaiser, Andrew ;

Heinrichs, Christian ;

Klebanoff, Christopher A. ;

Tagaya, Yutaka ;

Restifo, Nicholas P. .

JOURNAL OF IMMUNOLOGY, 2006, 176 (09) :5255-5266

[8] NK cells and polymorphonuclear neutrophils are both critical for IL-2-induced pulmonary vascular leak syndrome [J].

Assier, E ;

Jullien, V ;

Lefort, J ;

Moreau, JL ;

Di Santo, JP ;

Vargaftig, BB ;

Silva, JRLE ;

Thèze, J .

JOURNAL OF IMMUNOLOGY, 2004, 172 (12) :7661-7668

[9] High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].

Atkins, MB ;

Lotze, MT ;

Dutcher, JP ;

Fisher, RI ;

Weiss, G ;

Margolin, K ;

Abrams, J ;

Sznol, M ;

Parkinson, D ;

Hawkins, M ;

Paradise, C ;

Kunkel, L ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116

[10] Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome [J].

Baluna, R ;

Rizo, J ;

Gordon, BE ;

Ghetie, V ;

Vitetta, ES .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (07) :3957-3962

← 1 2 3 4 5 6 7 8 →